...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Re: Additional Exempt Distribution- 2023-03-31

It's only that one Hong Kong investor who has been accepting Nov 2023 warrants.  This, from the Apr 6 2023 "Interim financial statements/report" tells me everything I need to know about timing......

"....In connection with the additional CAD$1.7 million advanced by a relative of the Chief Executive Officer / Chairman of the Company, the Company issued a total of 1,350,000 warrants. Each warrant is exercisable at a price of $0.75 per underlying common share for a period of five years from the respective grant dates...."

(my bolding)

 

Share
New Message
Please login to post a reply